Hyperfine (HYPR) Jefferies Global Healthcare Conference summary

Technology and innovation

• Commercializes the first FDA-cleared, ultra-low field, portable brain MRI system, leveraging proprietary AI-powered technology and rapid iteration cycles.

• Platform provides diagnostic-quality imaging at 64 millitesla, covering all standard brain MRI sequences and is safe for use across diverse care settings.

• System is AI-enabled, with ongoing software improvements and a strong patent portfolio exceeding 150 patents.

• Integrated with hospital workflows, operable via tablet, and requires minimal specialized training.

• Achieved multiple regulatory clearances, including FDA, CE, and UKCA, and published nearly 50 papers across various clinical use cases.

Market opportunity and deployment

• Addresses unmet needs in neurological care by enabling accessible, affordable, and equitable brain MRI globally.

• Deployed in over 50 low-resource settings internationally, supported by partnerships such as with the Gates Foundation.

• U.S. market opportunity estimated at $1.5B for critical care and pediatric hydrocephalus, expanding to $16B with broader brain health applications.

• Plans to expand into outpatient and neurology office settings by late 2024 and early 2025, with CMS coverage anticipated.

• Recently entered the Indian market, targeting significant underpenetration in MRI access.

Clinical and economic impact

• Enables timely clinical decisions for acute and chronic neurological conditions, including stroke and Alzheimer's.

• Reduces risks and costs associated with transporting critically ill patients for conventional MRI.

• Provides economic benefits by freeing up conventional MRI capacity and reducing unnecessary patient transfers.

• Supports triage in remote settings, limiting costly referrals to conventional MRI.

• Broad FDA labeling allows scanning of all ages and conditions, with reimbursement already in place.